The antagonists of the two prostaglandin D2 receptors, prostaglandin D2 receptor 1 (DP1) and chemoattractant homologous receptor expressed on Th2 cells (CRTH2), may theoretically be a future approach to the treatment of tachycardia in MCAD. Here, PTGDR is linked to medium chain acyl-CoA dehydrogenase deficiency.